Somatostatin blocks the release of numerous growth factors and is therefore a potent inhibitor of cell division and/or secretion. It exerts its effects through binding to somatostatin receptors. Five different subtypes of such receptors are identified (SSTR1 to SSTR5), having various tissue expression. The detection of their presence in tumours can be performed on histological sections and has potential therapeutic implications
The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have increas...
The physiological actions of somatostatin-14 (SRIF: somatotrophin release inhibitory factor) recepto...
The majority of gastroenteropancreatic well-differentiated endocrine carcinomas (WDEC) express somat...
Neuroendocrine tumours (NETs) may occur at many sites in the body although the majority occur within...
International audienceSince its discovery three decades ago as an inhibitor of GH release from the p...
Five somatostatin receptor (sst) subtype genes, sst1, sst2, sst3, sst4 and sst5, have been cloned an...
The multiple actions of somatostatin are mediated by specific membrane-bound receptors present in al...
The pharmacological effects (i.e., inhibition of endocrine secretion and cell proliferation) mediate...
textabstractSomatostatin, a hormone which has an inhibitory influence on several physiological proce...
Peptide receptors involved in pathophysiological processes represent promising therapeutic targets. ...
Somatostatin (SST) is a small peptide that exerts inhibitory effects on a wide range of neuroendocri...
Somatostatin analogs for the diagnosis and therapy of neuroendocrine tumors (NETs) have been used in...
Somatostatin receptor subtype 2 (sst(2)) is widely expressed in neuroendocrine tumors and can be vis...
textabstractSomatostatin receptors expressed on tumor cells form the rationale for somatostati...
The physiological actions of somatostatin-14 (SRIF: somatotrophin release inhibitory factor) recepto...
The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have increas...
The physiological actions of somatostatin-14 (SRIF: somatotrophin release inhibitory factor) recepto...
The majority of gastroenteropancreatic well-differentiated endocrine carcinomas (WDEC) express somat...
Neuroendocrine tumours (NETs) may occur at many sites in the body although the majority occur within...
International audienceSince its discovery three decades ago as an inhibitor of GH release from the p...
Five somatostatin receptor (sst) subtype genes, sst1, sst2, sst3, sst4 and sst5, have been cloned an...
The multiple actions of somatostatin are mediated by specific membrane-bound receptors present in al...
The pharmacological effects (i.e., inhibition of endocrine secretion and cell proliferation) mediate...
textabstractSomatostatin, a hormone which has an inhibitory influence on several physiological proce...
Peptide receptors involved in pathophysiological processes represent promising therapeutic targets. ...
Somatostatin (SST) is a small peptide that exerts inhibitory effects on a wide range of neuroendocri...
Somatostatin analogs for the diagnosis and therapy of neuroendocrine tumors (NETs) have been used in...
Somatostatin receptor subtype 2 (sst(2)) is widely expressed in neuroendocrine tumors and can be vis...
textabstractSomatostatin receptors expressed on tumor cells form the rationale for somatostati...
The physiological actions of somatostatin-14 (SRIF: somatotrophin release inhibitory factor) recepto...
The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have increas...
The physiological actions of somatostatin-14 (SRIF: somatotrophin release inhibitory factor) recepto...
The majority of gastroenteropancreatic well-differentiated endocrine carcinomas (WDEC) express somat...